CD112R antibody
Quick Overview for CD112R antibody (ABIN6253480)
Target
Reactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- anti-CD112R (mouse), pAb (IN109)
-
Characteristics
- Polyclonal Antibody. Recognizes mouse CD112R. Does not cross-react with human CD112R. Source: Rabbit. Application: ELISA, WB. Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide. CD112 (also called Nectin-2 or poliovirus receptor-related 2 protein) is a type I transmembrane glycoprotein and a member of the Ig gene superfamily (IGSF). CD112/Nectin-2 functions as an adhesion molecule involved in the formation of cell junctions and interactions with other Nectin-family molecules. Nectin-2 is a also a surface marker of some endothelial cells and regulates migration, proliferation and angiogenesis. CD112 functions as an immune checkpoint regulator by modulating T cell signaling, either as a costimulator of T cell function, or as a coinhibitor of T cells proliferation by binding to the receptors CD226 or TIGIT (T cell Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain), respectively. The binding of CD112 ligand to these receptors is weak compared to CD155. Recently, a new receptor of CD112, called CD112R or PVRIG (Poliovirus receptor-related immunoglobulin domain-containing protein) has been characterized, showing high affinity to CD112. CD112R is a new coinhibitory receptor of the PVR family for human T cells, inhibiting TCR-mediated signals upon binding to CD112/Nectin-2. CD112R is preferentially expressed in T lymphocytes and NK cells. Cancer cells evade immune responses as a result of an immunosuppressive tumor microenvironment and CD112R, by playing a role in the regulation of the immune system, could be a new attractive cancer immunotherapy target.
-
Immunogen
- Recombinant mouse CD112R.
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.
-
-
- CD112R
-
Background
-
Alternate Names/Synonyms: CD112 Receptor, Poliovirus Receptor-related Immunoglobulin Domain-containing Protein, Transmembrane Protein PVRIG
Product Description: CD112 (also called Nectin-2 or poliovirus receptor-related 2 protein) is a type I transmembrane glycoprotein and a member of the Ig gene superfamily (IGSF). CD112/Nectin-2 functions as an adhesion molecule involved in the formation of cell junctions and interactions with other Nectin-family molecules. Nectin-2 is a also a surface marker of some endothelial cells and regulates migration, proliferation and angiogenesis. CD112 functions as an immune checkpoint regulator by modulating T cell signaling, either as a costimulator of T cell function, or as a coinhibitor of T cells proliferation by binding to the receptors CD226 or TIGIT (T cell Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain), respectively. The binding of CD112 ligand to these receptors is weak compared to CD155. Recently, a new receptor of CD112, called CD112R or PVRIG (Poliovirus receptor-related immunoglobulin domain-containing protein) has been characterized, showing high affinity to CD112. CD112R is a new coinhibitory receptor of the PVR family for human T cells, inhibiting TCR-mediated signals upon binding to CD112/Nectin-2. CD112R is preferentially expressed in T lymphocytes and NK cells. Cancer cells evade immune responses as a result of an immunosuppressive tumor microenvironment and CD112R, by playing a role in the regulation of the immune system, could be a new attractive cancer immunotherapy target.
Target
-
